Accuracy of surveillance serum squamous cell carcinoma antigen for cervical cancer recurrence after definitive chemoradiation
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Elevated serum squamous cell carcinoma antigen (SCCA) during surveillance is highly specific for cervical cancer recurrence. However, its utility may be limited in patients with normal pre-treatment SCCA levels.
Area Of Science
- Oncology
- Biomarkers
- Gynecologic Oncology
Background
- Cervical cancer recurrence is a significant clinical challenge.
- Early detection of recurrence can improve patient outcomes.
- Serum squamous cell carcinoma antigen (SCCA) is a known prognostic biomarker.
Purpose Of The Study
- To evaluate the sensitivity and specificity of serum SCCA for detecting cervical cancer recurrence during surveillance.
- To assess the predictive value of SCCA in patients with varying pre-treatment SCCA levels.
Main Methods
- Retrospective analysis of serum SCCA levels (pre-treatment and follow-up) in 227 cervical cancer patients treated with radiotherapy.
- Enzyme-linked immunosorbent assay (ELISA) used for SCCA measurement.
- Calculation of sensitivity, specificity, PPV, and NPV for recurrence detection.
Main Results
- Elevated follow-up SCCA was significantly associated with recurrence (p=0.02).
- Overall cohort sensitivity was 38.5% and specificity was 97.1%.
- Patients with elevated pre-treatment SCCA showed higher sensitivity (54.5%) for detecting recurrence.
Conclusions
- Surveillance serum SCCA demonstrates high specificity and negative predictive value for cervical cancer recurrence.
- The utility of serum SCCA for recurrence detection may be limited in patients with normal pre-treatment levels.
- Elevated SCCA levels are associated with isolated pelvic recurrence.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.